Polysaccharide PS-A obtained from barrenwort deriving from plants belonging to the genus Epimedium, process for preparation thereof and phylactic and immunostimulating agents comprising said polysaccharide PS-A effective component

TECHNICAL FIELD
The present invention relates to a polysaccharide (named PS-A) obtained from barrenwort deriving from plants belonging to the genus Epimedium of the family Berberidaceae and having the following physicochemical properties, a process for preparation thereof, and an agent of nonspecific resistance against infection (hereinafter referred to as a phylactic agent) and an immunostimulating agent comprising polysaccharide PS-A as an effective component:
1. Elementary analysis: C=40.92, H=6.17, Ash=very small;
2. Molecular weight: 75,000.+-.25,000 (average molecular weight);
3. Decomposition point: 205.degree. C.;
4. pH: 7.0 (solution of 100 mg of PS-A in 50 ml of water);
5. Specific rotatory power: [.alpha.].sub.D.sup.19 =-23.6.degree. (in H.sub.2 O, c=0.527);
6. Infrared absoption spectrum: .nu..sub.max.sup.KBr (cm.sup.-1)/3400, 2900, 1620, 1400 1230, 1060;
7. Ultraviolet absorption spectrum: Maximum absorption is not recognized in the range of 240-400 nm.;
8. Outward form: White or faint brown, amorphous powder;
9. Solubility:
(a) Soluble in water;
(b) Insoluble in methanol, ethanol, acetone, ethyl acetate, diethyl ether, hexane or chloroform; PG,4
10. Color reactions:
Positive to the following reactions: (a) anthrone-sulfuric acid reaction; (b) Molisch's reaction; (c) skatol reaction; and (d) Bial's reaction;
Negative to the following reactions: (a) ninhydrin reaction; (b) 2,4-DNP reaction; (c) Selivanoff's reaction; (d) naphthoresorcinol reaction; and (e) carbazol-sulfuric acid reaction;
11. Component sugars: Arabinose and galactose;
12. Homogeneity: Homgeneity is proved according to ultracentrifugation, electrophoresis and gel filtration.
BACKGROUND ART
As the barrenwort deriving from plants belonging to the genus Epimedium, there are known Epimedium macranthum, M. et. D. var. violaceum, Fr., Epimedium sagittatum, Bak., Epimedium macranthum, M. et. D., Epimedium koreanum, Nak., etc. These plants are perennial herbs growing naturally in Japan, China and Korea, etc. The barrenwort is a crude drug obtained from a single species or a mixture of two or more of species belonging to the genus Epimedium by cutting down the plants at roots in June or July and drying them in the shade under good ventilation while keeping out rain and dew. The plants belonging to the genus Epimedium are perennials belonging to the family Berberidaceae, having the height of 30 to 60 cm and growing wild in fields and mountains in Japan, China, Korea or the like. The barrenwort marketed in Japan and Korea derives from Epimedium macranthum, M. et D. var. violaceum, Fr. or Epimedium koreanum Nak.; the barrenwort marketed in China, from Epimedium sagittatum Bak. or Epimedium koreanum Nak. In the field of Chinese medicines, herb of any plants belonging to the genus Epimedium is called "Yinyanghuo" irrespective of species of the plants and is infused and used as a cordial or tonic medicine. Components of this barrenwort have been studied from old and reports have been published. For example, by Akai et al. [Yakugaku Zasshi, 55, 537, 705, 719, 788 and 1139 (1935)] and Tomita et al. [Yakugaku Zasshi, 77, 114 and 212 (1957)], the substance called Icariin and the substances caled Des-O-methyl Icariin and Magnoflorine were found and the chemical structures of the respective substances have been determined. As to the phamacological characteristics, it has been reported for example by Maeda [Tokio Izi Sinsi, No. 2795, 2133 (1932)], Miyake [Okayama Igakkai Zasshi, 49, (10) 2043 (1937 )] and Hirashima et al. [Clinical Report, 4, 139 (1970)] that an extract from the barrenwort has the sperm-excitosecretory effect the hypotensive effect and the blood sugar descending effect. But their details are still unclear in many points.
We made researches on this barrenwort and succeeded in obtaining an extract having an immunostimulating activity by extracting plants belonging to the genus Epimedium. Japanese patent applications Nos. 21152/1980, 57424/1980 and 83539/1980 were filed on the basis of this finding. We further made researches to succeed in extraction and isolation of the polysaccharide PS-A, as shown in the following flow chart, having an phylactic activity and an immunostimulating activity. We have now completed the present invention based on this success. ##STR1##
DISCLOSURE OF THE INVENTION
First of all, extraction, isolation and purification of polysaccharide PS-A will be described.
Step 1
A barrenwort deriving from plants belonging to the genus Epimedium is extracted with a mixed solvent of water and a water-miscible organic solvent or with water, and the obtained extract is concentrated under reduced pressure. As the water-miscible organic solvent there can be used, for example, lower alcohols such as methanol, ethanol and isopropanol, ketones such as acetone and water-miscible ethers such as dioxane and the like. A mixture of two or more of these water-miscible solvents may also be used. Furthermore, lower aliphatic acids such as acetic acid having a concentration lower than 1 normality, water-miscible lower amines such as ethanol amine having a concentration lower that 1 mol/l can be used as the extraction solvent. In view of the concentration opration, it is preferred that the operation of obtainig the intended aqueous extract be carried out by using a mixed solvent of a water-miscible organic solvent and water and that the amount of the organic solvent be smaller than 50% by volume. In the present invention, herb of barrenwort commercially available in Japan, China or the like may be used as it is, but it is preferred that it be used after it has been finely divided into pieces.
Step 2
The so obtained aqueous extract is then treated by an organic solvent or solvents.
This operation is accomplished by adding one or more organic solvents selected from lower aliphatic esters such as ethyl acetate, halogenated hydrocarbons such as chloroform, hardly water-soluble ethers such as diethyl ether and aliphatic hydrocarbons such as n-hexane and the like, sufficiently shaking the mixture and collecting the aqueous layer alone. The obtained aqueous layer is subjected to the same operation 3 to 5 times and is heated on a water bath to remove the organic solvent left in a small amount, and then filtered to obtain an aqueous extract treated by the organic solvent or solvents. There may be adopted a method in which Step 2 is first conducted and Step 1 is then carried out.
Step 3
A water-soluble organic solvent is added to the aqueous extract obtained in step 2 to effect the precipitation. The formed precipitate is recovered by filtration and is washed with a water-soluble organic solvent. The washed precipitate is poured into water. Then, a water-soluble organic solvet is added to the solution to effect the precipitation again. The formed precipitate is recovered by filtration and dried under reduced pressure to obtain an extract. As the water-soluble organic solvent, there may be used, for example, lower alcohols such as methanol and ethanol and ketones such as acetone and the like. A mixture of two or more of these organic solvents may also be used. The so obtained precipitate may be purified by extraction with water. More specifically, the precipitate is mixed with water at room temperature, and the mixture is sufficiently stirred and is then filtered. The filtrate is concentrated to dryness under reduced pressure for purification.
Step 4
The precipitate obtained in Step 3 is dissolved in water and then a long-chained quaternary ammonium salt is added thereto to remove a resultant complex.
One example of the operation will be now described.
The precipitate obtained in Step 3 is dissolved in an inorganic salt aqueous solution whose amount is 50 to 80 times (V/W) that of the precipitate. It is preferred that the inorganic salt aqueous solution be 0.01 to 0.05 mol/l of aqueous solution of sodium sulfate or sodium chloride. Then a long-chained quaternary ammonium salt such as cetyltrimethylammonium salt or cetylpyrdinium salt is added to the solution in an amount 0.5 to 3 times (W/W) that of the precipitate obtained in Step 3. The resultant precipitate is removed by filtration or centrifugation. A water-soluble organic solvent is added to the recovered filtrate in an amount more than 3 times (V/V) that of the filtrate and resultant precipitate is recovered by filtration.
Step 5
The precipitate obtained in Step 3 is dissolved in water and then low molecular substances are removed therefrom.
One example of the operation will be now described.
Water is added to the precipitate obtained in Step 4 in an amount 300 to 400 times (V/W) that of the precipitate and the mixture is adequately stirred under heating at 35.degree. to 45.degree. C. for dissolution. The solution is ultrafiltered through a membrane with nominal molecular weight ultrafiltration value of 1,000 to remove the substances passing through the filtering membrane. Water is added to the condensate caught by the membrane in an amount of 5 to 10 times (V/V) that of the condensate and the mixture is adequately stirred, diluted and ultrafiltered again. This operation is repeated a few times to completely remove the substances passing through the membrane. The condensate caught by the membrane is recovered, and water is added for dilution to the recovered condensate in an amount of 2 to 5 times (V/V) that of the condensate. Then, a water-soluble organic solvent is added to the solution in an amount of more than 4 times (V/V) that of the solution to obtain extract A as precipitate.
Step 6
The intended polysaccharide PS-A can be obtained by subjecting extract A to chromatography. In the chromatography, a carrier having a molecular sieve effect may be used. Before this chromatography, chromatography with an adsorbent may be effected.
The operation will be shown below concretely.
Extract A is dissolved in water and the solution is subjected to the chromatography using a carrier having a molecular sieve effect such as gel filtration. A fraction shown as Fr-1 in FIG. 1 is collected to obtain the polysaccharide PS-A of the present invention. Polysaccharides (named PS-B and PS-C) are also obtained from fractions Fr-2 and Fr-3, respectively, in FIG. 1.
The following operation may be effected for the purpose of obtaining the polysaccharides of high purities:
Extract A is subjected to adsorption chromatography. After the elution with water, the eluted fraction is separated out. (Polysaccharide PS-B is obtained by concentrating this fraction to dryness under reduced pressure.) As the adsorbent used in this step, there may be mentioned, for example, a polyamide resin or an anion-exchange resin. The polyamide resin is preferred. Then, the elution is continued by using a volatile, weakly alkaline aqueous solution such as aqueous ammonia solution as the elution solvent. The eluted fraction is taken and concentrated to dryness under reduced pressure or freeze-dried to obtain extract B.
Extract B is dissolved in water and the solution is subjected to chromatography using a carrier having a molecular sieve effect such as gel filtration. A fraction eluted out first is taken to obtain polysaccharide PS-A. (PS-C can be obtained from the remaining fraction.)
The polysaccharide PS-A has the following physicochemical properties:
1. Elementary analysis: C=40.92; H=6.17; Ash=very small;
2. Molecular weight: 75,000.+-.25,000 (average molecular weight);
It was measured according to the method reported in P. Andrews, Methods of Biochemical Analysis, ed. by D. Glick, John Wiley & Sons, Inc., New York, 18 2 (1970). The filler used was Sephadex G-200 (produced by Pharmacia Fine Chemical Co., Ltd., Sweden). The column used had 2.5 mm in diameter and 100 cm in length. The elusion liquid used was 0.1 mol aqueous sodium chloride solution at a rate of 10 ml/hour. Standards used for determining calibration curves were Dextran T-500 (M.W. 487,000), Dextran T-70 (M.W. 70,300) and Dextran T-40 (M.W. 39,000) (produced by Pharmacia Fine Chemical Co., Ltd., Sweden).
3. Decomposition point: 205.degree. C.;
4. pH: 7.0 (solution of 100 mg of PS-A in 50 ml of water);
5. Specific rotatory power: [.alpha.].sub.D.sup.19 =-23.6.degree. (in H.sub.2 O, c=0.527);
6. Infrared absorption spectrum: .nu..sub.max.sup.KBr (cm.sup.-1)/3400, 2900, 1620, 1400 1230, 1060;
7. Ultraviolet absorption spectrum: Maximum absorption is not recognized in the range of 240-400 nm.;
8. Outward form: White or faint brown, amorphous powder;
9. Solubility:
(a) Soluble in water;
(b) Insoluble in methanol, ethanol, acetone, ethyl acetate, diethyl ether, hexane or chloroform;
10. Color reactions:
Positive to the following reactions: (a) anthrone-sulfuric acid reaction; (b) Molisch's reaction; (c) skatol reaction; and (d) Bial's reaction;
Negative to the following reactions: (a) ninhydrin reaction; (b) 2,4-DNP reaction; (c) Selivanoff's reaction; (d) naphthoresorcinol reaction; and (e) carbazol-sulfuric acid reaction;
11. Component sugars:
5 ml of 1N-sulfuric acid is added to 20 mg of the polysaccharide PS-A and the mixture is refluxed at 100.degree. C. for 2 hours; after cooling, it is neutralized with barium hydroxide; the precipitate formed is filtered out and the filtrate is subjected to paper chromatography to confirm the presence of arabinose and galactose;
12. Homogeneity:
(a) Ultracentrifugation: Homogeneity is proved by the equilibrium density-gradient centrifugation (120,000 G.times.72 hours, CaCl.sub.2);
(b) Electrophoresis: Homogeneity is proved by the electrophoresis using a cellulose acetate membrane (20-25 V/cm, 2 hours);
(c) Gel filtration: Homogeneity is proved by the gel filtration using Sephadex G-100.
The polysaccharides PS-B and PS-C have the following physicochemical properties:
______________________________________Item PS-B PS-C______________________________________1. Elementary C = 37.69, H = 6.00 C = 40.75, H = 6.28 analysis Ash = very small Ash = very small2. Molecular 50,000 .+-. 25,000 25,000 .+-. 15,000 weight (aver- age molecu- lar weight)3. Decomposi- 200.degree. C. 175.degree. C. tion point4. pH 6.9 7.05. Specific rota- [.alpha.] .sub.D.sup.19 = -0.5.degree. [.alpha.] .sub.C.sup.19 = -12.6.degree. tory power (in H.sub.2 O, c = 0.756) (in H.sub.2 O, c = 0.512)6. Infrared See FIG. 3. See FIG. 4. absorption .nu. .sub.max .sup.KBr(cm.sup.-1)/3350, .nu. .sub.max.sup.KBr(cm.sup.-1)/3300.about. 7 spectrum 2920, 1630, 1550 3400, 2900, 1600, 1420, 1100 1400, 1040.about.1060______________________________________
As to the items 7. Ultraviolet absorption spectrum, 8. Outward form, 9. Solubility, 10. Color reactions, 11. Component sugars and 12. Homogeneity, the polysaccharides PS-B and PS-C have the same physicochemical properties as those of the polysaccharide PS-A.
Moreover, the extracts A and B have the following physicochemical properties:
______________________________________Item Extract A Extract B______________________________________1. Outward form Liver brown powder Faint brown or brown powder2. pH 7.0 7 03. Infrared See FIG. 5. See FIG. 6. absorption spec- .nu. .sub.max.sup.KBr(cm.sup.-1)/3400, .nu. .sub.max.sup.KBr(cm.sup.-1)/3200 trum 2900, 1600, 1400, 1600, 1400, 1100 10504. Ultraviolet Maximum absorption is not recognized absorption spec- in the range of 240-400 nm. trum5. Solubility (a) Soluble in water. (b) Insoluble in methanol, ethanol, acetone, ethyl acetate, diethyl ether, hexane or chloroform.6. Color reaction Positive to the following reactions: (a) anthrone-sulfuric acid reaction, (b) Molisch's reaction, (c) skatol reaction and (d) Bial's reaction. Negative to the following reactions: (a) ninhydrin reaction, (b) 2,4-DNP reaction, (c) Selivanoff's reaction, (d) naphthoresorcinol reaction and (e) carbazol-sulfuric acid reaction.7. Component 5 ml of 1N--sulfuric acid is added sugars to 20 mg of the extract A or B and the mixture is refluxed under heating for 2 hours. After cooling, it is neutralized with barium hydroxide. The precipitate formed is filtered and the filtrate is subjected to paper chromatography to confirm the presence of arabinose and galactose.______________________________________
The following tests (I)-(III) were effected for confirming the utility of the above polysaccharide PS-A:
(I) TEST FOR JUDGING PHYLACTIC EFFECTS
(1) Effects on subjects in normal state
A sample was administered subcutaneously to the back of each of 5-weeks-old male mice of the ICR/JCL strain having a body weight of about 25 g (each group consiting of 10 mice) once a day continuously for five days (5 times in total). Physiological saline solution (hereinafter referred to as PS) was given to a control group. On the sixth day, E. coli ML 4707 was challenged to each mouse by the intraperitoneal injection. The tests were carried out in the same manner as above using Ps. aeruginosa 70P II, S. aureus Smith diffuse, K. pneumoniae GN 6445, S. enteritidis 116-54 and P. vulgaris GN 5737. Seven days after the challenge, viable count was examined. The results are shown in Tables 1-6.
TABLE 1______________________________________Effects on E. coli 1.0 .times. 3.2 .times. 1.0 .times.bacterial challenge (cells/mouse) 10.sup.7 10.sup.6 10.sup.6______________________________________Viable count in control group (%) 0 30 60Viable count in 0.1 mg/kg body 10 30 70polysaccharide wt./dayPS-A-treated 0.5 mg/kg body 20 40 100group (%) wt./day 2.5 mg/kg body 40 80 100 wt./dayReferenceViable count in 0.5 mg/kg body 10 20 40polysaccharide wt./dayPS-B-treated 2.5 mg/kg body 20 60 70group (%) wt./day 12.5 mg/kg body 40 80 80 wt./dayViable count in 0.3 mg/kg body 10 30 60polysaccharide wt./dayPS-C-treated 1.5 mg/kg body 20 40 70group (%) wt./day 7.5 mg/kg body 30 50 90 wt./dayViable count 1.0 mg/kg body 10 30 40in extract wt./dayA-treated 5.0 mg/kg body 20 40 60group (%) wt./day 25.0 mg/kg body 40 60 80 wt./dayViable count 0.5 mg/kg body 10 20 40in extract wt./dayB-treated 2.5 mg/kg body 20 40 50group (%) wt./day 12.5 mg/kg body 30 50 100 wt./day______________________________________
TABLE 2______________________________________Effects on Ps. aeruginosa 5.0 .times. 1.6 .times. 5.0 .times.Bacterial challenge (cells/mouse) 10.sup.7 10.sup.7 10.sup.6______________________________________Viable count in control group (%) 0 20 40Viable count in 0.1 mg/kg body 20 20 70polysaccharide wt./dayPS-A-treated 0.5 mg/kg body 20 50 90group (%) wt./day 2.5 mg/kg body 30 50 100 wt./dayReferenceViable count in 0.5 mg/kg body 10 30 20polysaccharide wt./dayPS-B-treated 2.5 mg/kg body 20 30 60group (%) wt./day 12.5 mg/kg body 30 70 100 wt./dayViable count in 0.3 mg/kg body 10 30 30polysaccharide wt./dayPS-C-treated 1.5 mg/kg body 10 30 50group (%) wt./day 7.5 mg/kg body 30 50 100 wt./dayViable count 1.0 mg/kg body 0 20 20in extract wt./dayA-treated 5.0 mg/kg body 10 40 60group (%) wt./day 25.0 mg/kg body 30 50 80 wt./dayViable count 0.5 mg/kg body 10 10 30in extract wt./dayB-treated 2.5 mg/kg body 20 50 70group (%) wt./day 12.5 mg/kg body 30 50 80 wt./day______________________________________
TABLE 3______________________________________Effects on S. aureus 2.0 .times. 1.0 .times. 5.0 .times.Bacterial challenge (cells/mouse) 10.sup.9 10.sup.9 10.sup.8______________________________________Viable count in control group (%) 0 10 50ReferenceViable count in 0.1 mg/kg body 30 30 70polysaccharide wt./dayPS-A-treated 0.5 mg/kg body 40 50 70group wt./day 2.5 mg/kg body 60 60 100 wt./dayViable count in 0.5 mg/kg body 10 30 60polysaccharide wt./dayPS-B-treated 2.5 mg/kg body 10 40 70group (%) wt./day 12.5 mg/kg body 20 40 90 wt./dayViable count in 0.3 mg/kg body 10 20 50polysaccharide wt./dayPS-C-treated 1.5 mg/kg body 10 30 80group (%) wt./day 7.5 mg/kg body 30 50 90 wt./dayViable count 1.0 mg/kg body 10 20 60in extract wt./dayA-treated 5.0 mg/kg body 10 40 70group (%) wt./day 25.0 mg/kg body 20 50 80 wt./dayViable count 0.5 mg/kg body 10 20 60in extract wt./dayB-treated 2.5 mg/kg body 20 40 70group (%) wt./day 12.5 mg/kg body 20 60 90 wt./day______________________________________
TABLE 4______________________________________Effects on K. poneumoniae 5.0 .times. 1.3 .times. 5.0 .times.Bacterial challenge (cells/mouse) 10.sup.7 10.sup.7 10.sup.6______________________________________Viable count in control group (%) 0 20 60Viable count in 0.1 mg/kg body 10 40 90polysaccharide wt./dayPS-A-treated 0.5 mg/kg body 40 50 100group (%) wt./day 2.5 mg/kg 40 70 100 wt./dayReferenceViable count in 0.5 mg/kg body 10 30 60polysaccaride wt./dayPS-B-treated 2.5 mg/kg body 50 60 100group (%) wt./day 12.5 mg/kg body 60 80 100 wt./dayViable count in 0.3 mg/kg body 10 30 70polysaccharide wt./dayPS-C-treated 1.5 mg/kg body 30 40 90group (%) wt./day 7.5 mg/kg body 30 60 100 wt./dayViable count 1.0 mg/kg body 10 20 60in extract wt./dayA-treated 5.0 mg/kg body 30 40 80group (%) wt./day 25.0 mg/kg body 40 60 90 wt./dayViable count 0.5 mg/kg body 20 30 60in extract wt./dayB-treated 2.5 mg/kg body 40 50 90group (%) wt./day 12.5 mg/kg body 40 80 100 wt./day______________________________________
TABLE 5______________________________________Effect on S. enteritidis 1.0 .times. 1.0 .times. 1.0 .times.Bacterial challenge (cells/mouse) 10.sup.5 10.sup.4 10.sup.3______________________________________Viable count in Control group (%) 0 0 30Viable count in 0.1 mg/kg body 10 20 60polysaccharide wt./dayPS-A-treated 0.5 mg/kg body 10 20 80group (%) wt./day 2.0 mg/kg body 20 20 90 wt./dayReferenceViable count in 0.5 mg/kg body 0 0 30polysaccharide wt./dayPS-B-treated 2.5 mg/kg body 0 0 40group (%) wt./day 12.5 mg/kg body 10 30 70 wt./dayViable count in 0.3 mg/kg body 0 0 30polysaccharide wt./dayPS-C-treated 1.5 mg/kg body 0 10 50group (%) wt./day 7.5 mg/kg body 10 30 60 wt./dayViable count 1.0 mg/kg body 0 0 30in extract wt./dayA-treated 5.0 mg/kg body 0 0 40group (%) wt./day 25.0 mg/kg body 10 30 50 wt./dayViable count 0.5 mg/kg body 0 0 30in extract wt./dayB-treated 2.5 mg/kg body 0 10 50group (%) wt./day 12.5 mg/kg body 10 30 60 wt./day______________________________________ Note Fourteen days after the challenge, viable count was examined.
TABLE 6______________________________________Effects on P. vulgaris 5.0 .times. 1.3 .times. 5.0 .times.Bacterial challenge (cells/mouse) 10.sup.8 10.sup.8 10.sup.7______________________________________Viable count in control group (%) 0 10 10Viable count in 0.1 mg/kg body 30 40 100polysaccharide wt./dayPS-A-treatedd 0.5 mg/kg body 30 50 90group (%) wt./day 2.5 mg/kg body 40 50 80 wt./dayReferenceViable count in 0.5 mg/kg body 20 30 80polysaccharide wt./dayPS-B-treated 2.5 mg/kg body 30 40 80group (%) wt./day 12.5 mg/kg body 30 40 100 wt./dayViable count in 0.3 mg/kg body 20 30 50polysaccharide wt./dayPS-C-treated 1.5 mg/kg body 20 40 70group (%) wt./day 7.5 mg/kg body 30 50 100 wt./dayViable count 1.0 mg/kg body 10 20 40in extract wt./dayA-treated 5.0 mg/kg body 20 30 50group (%) wt./day 25.0 mg/kg body 30 40 70 wt./dayViable count 0.5 mg/kg body 10 30 40in extract wt./dayB-treated 2.5 mg/kg body 20 30 50group (%) wt./day 12.5 mg/kg body 20 40 70 wt./day______________________________________
In the above tests, the phylactic effects of polysaccharides PS-A, PS-B nd PS-C, and extracts A and B on E. coli, Ps. aeruginosa, S. aureus, K. pneumoniae, S. enteritidis and P. vulgaris were recognized.
(2) Effect on subjects in the immunosuppressive state
A sample was administered subcutaneously to the back of each of 5-weeks-old female mice of the ICR/JCL strain having a body weight of about 25 g (each group consisting of 10 mice) once a day continuously for four days (4 times in total). PS was given to a control group. On the first day of the administration, cyclophosphamide (200 mg/kg body weight) was injected thereto by the intraperitoneal injection. On the next day of the final administration (i.e. on the fifth day), E. coli ML 4707 was challenged to each mouse by the intraperitoneal injection. The tests were carried out in the same manner as above using Ps. aeruginosa 70P II, S. aureus Smith diffuse, and P. vulgaris GN 5737. Seven days after the challenge, viable count was examined. The results are shown in Tables 7-10.
TABLE 7______________________________________Effects on E. coli in theimmunosuppressive stateBiological challenge (cells/mouse) 1.0 .times. 10.sup.6 5.0 .times. 10.sup.5______________________________________Viable count in control group (%) 0 20Viable count in 0.2 mg/kg body wt./day 50 70polysaccharide 1.0 mg/kg body wt./day 100 100PS-A-treatedgroup (%)ReferenceViable count in 1.0 mg/kg body wt./day 30 50polysaccharide 5.0 mg/kg body wt./day 70 80PS-B-treatedgroup (%)Viable count in 0.6 mg/kg body wt./day 40 50polysaccharide 3.0 mg/kg body wt./day 60 70PS-C-treatedgroup (%)Viable count 2.0 mg/kg body wt./day 30 50in extract 10.0 mg/kg body wt./day 60 70A-treatedgroup (%)Viable count 1.0 mg/kg body wt./day 40 50in extract 5.0 mg/kg body wt./day 60 70B-treatedgroup (%)______________________________________
TABLE 8______________________________________Effects on Ps. aeruginosaimmunosuppressive stateBiological challenge (cells/mouse) 2.0 .times. 10.sup.6 5.0 .times. 10.sup.5______________________________________Viable count in control group (%) 0 30Viable count in 0.2 mg/kg body wt./day 30 80polysaccharide 1.0 mg/kg body wt./day 70 100PS-A-treatedgroup (%)ReferenceViable count in 1.0 mg/kg body wt./day 20 50polysaccharide 5.0 mg/kg body wt./day 70 90PS-B-treatedgroup (%)Viable count in 0.6 mg/kg body wt./day 30 50polysaccharide 3.0 mg/kg body wt./day 60 80PS-C-treatedgroup (%)Viable count 2.0 mg/kg body wt./day 10 30in extract 10.0 mg/kg body wt./day 50 60A-treatedgroup (%)Viable count 1.0 mg/kg body wt./day 20 40in extract 5.0 mg/kg body wt./day 50 70B-treatedgroup (%)______________________________________
TABLE 9______________________________________Effects on S. aureus in theimmunosuppressive stateBiological challenge (cells/mouse) 5.0 .times. 10.sup.7 5.0 .times. 10.sup.6______________________________________Viable count in control group (%) 20 40Viable count in 0.2 mg/kg body wt./day 90 100polysaccharide 1.0 mg/kg body wt./day 100 100PS-A-treatedgroup (%)ReferenceViable count in 1.0 mg/kg body wt./day 50 70polysaccharide 5.0 mg/kg body wt./day 100 100PS-B-treatedgroup (%)Viable count in 0.6 mg/kg body wt./day 50 70polysaccharide 3.0 mg/kg body wt./day 90 100PS-C-treatedgroup (%)Viable count 2.0 mg/kg body wt./day 40 70in extract 10.0 mg/kg body wt./day 80 90A-treatedgroup (%)Viable count 1.0 mg/kg body wt./day 50 70in extract 5.0 mg/kg body wt./day 70 90B-treatedgroup (%)______________________________________
TABLE 10______________________________________Effects on P. vulgaris in theimmunosuppressive stateBiological challenge (cells/mouse) 1.0 .times. 10.sup.7 2.0 .times. 10.sup.6______________________________________Viable count in control group (%) 0 30Viable count in 0.2 mg/kg body wt./day 20 100polysaccharide 1.0 mg/kg body wt./day 70 100PS-A-treatedgroup (%)ReferenceViable count in 1.0 mg/kg body wt./day 20 60polysaccharide 5.0 mg/kg body wt./day 60 80PS-B-treatedgroup (%)Viable count in 0.6 mg/kg body wt./day 10 50polysaccharide 3.0 mg/kg body wt./day 50 70PS-C-treatedgroup (%)Viable count 2.0 mg/kg body wt./day 10 40in extract 10.0 mg/kg body wt./day 40 60A-treatedgroup (%)Viable count 1.0 mg/kg body wt./day 10 50in extract 5.0 mg/kg body wt./day 50 80B-treatedgroup (%)______________________________________
Polysaccharide PS-A, PS-B and PS-C and extracts A and B exhibited the phyractic effects on E. coli, Ps. aeruginosa, S. aureus and P. vulgaris even in the immunosuppressive state.
(3) Combination with antibiotics
A sample was administered subcutaneously to the back of each of 5-weeks-old male mice of the ICR/JCL strain having a body weight of about 25 g (each group consisting of 10 mice) once a day continuously for five days (5 times in total). PS was given to a control group. On the sixth day, 1.0.times.10.sup.7 cells of E. coli ML 4707 was challenged thereto by the intraperitoneal injection. 12.5 mg/kg of ampicillin (Ampicillin sodium for injection; produced by Toyama Kagaku Co., Ltd., Japan) was administered to each mouse twice (directly after the intraperitoneal injection and 4 hours thereafter). Seven days after the challenge, viable count was examined. The results are shown in Table 11.
TABLE 11______________________________________Effects obtained by the combination with antibioticsItem Viable count (%)______________________________________Control group 0Group treated with only ampicillin 20Group treated with polysaccharide PS-A 10(0.1 mg/kg body wt./day)Group treated with polysaccharide PS-A 100(0.1 mg/kg body wt./day) + ampicillinReferenceGroup treated with polysaccharide PS-B 0(0.5 mg/kg body wt./day)Group treated with polysaccharide PS-B 50(0.5 mg/kg body wt./day) + ampicillinGroup treated with polysaccharide PS-C 0(0.3 mg/kg body wt./day)Group treated with polysaccharide PS-C 50(0.3 mg/kg body wt./day) + ampicillinGroup treated with extract A 0(1.0 mg/kg body wt./day)Group treated with extract A 30(1.0 mg/kg body wt./day) + ampicillinGroup treated with extract B 0(0.5 mg/kg body wt./day)Group treated with extract B 40(0.5 mg/kg body wt./day) + ampicillin______________________________________
Polysaccharides PS-A, PS-B and PS-C, extracts A and B exhibited their combined effect when they were used in combination with the antibiotic.
(4) Effects used in combination with an antibiotic on subjects in the immunosuppressive state
A sample was administered subcutaneously to the back of each of 5-weeks-old female mice of the ICR/JCL strain having a body weight of about 25 g (each group consisting of 10 mice) once a day continuously for four days (4 times in total). PS was given to a control group. On the first day, 200 mg/kg of cyclophosphamide was injected to them by the intraperitoneal injection. On the next day of the final administration (i.e. on the fifth day), 1.0.times.10.sup.6 cells of E. coli ML 4707 was challenged thereto by the intraperitoneal injection. One hour thereafter, 6.25 mg/kg of ampicillin (Ampicillin-sodium for injection; produced by Toyama Kagaku Co., Ltd., Japan) was administered to the back of each mouse by the subcutaneous injection. Seven days after the challenge, viable count was examined. The results are shown in Table 12.
TABLE 12______________________________________Effects obtained by the combinationwith antibiotics on subjects in theimmunosuppressive stateItem Viable count (%)______________________________________Control group 0Group treated with only ampicillin 10Group treated with polysaccharide PS-A 0(0.1 mg/kg body wt./day)Group treated with polysaccharide PS-A 100(0.1 mg/kg body wt./day) + ampicillinReferenceGroup treated with polysaccharide PS-B 0(0.5 mg/kg body wt./day)Group treated with polysaccharide PS-B 40(0.5 mg/kg body wt./day) + ampicillinGroup treated with polysaccharide PS-C 0(0.3 mg/kg body wt./day)Group treated with polysaccharide PS-C 50(0.3 mg/kg body wt./day) + ampicillinGroup treated with extract A 0(1.0 mg/kg body wt./day)Group treated with extract A 30(1.0 mg/kg body wt./day) + ampicillinGroup treated with extract B 0(0.5 mg/kg body wt./day)Group treated with extract B 30(0.5 mg/kg body wt./day) + ampicillin______________________________________
Polysaccharides PS-A, PS-B nd PS-C and extracts A and B exhibited their combined effects when they were used in combination with the antibiotic even in the immunosuppressive state.
It is apparent from the above phylaxios tests (1)-(4) that all of the polysaccharides PS-A, PS-B and PS-C and extracts A and B have the phylactic effects.
Amoung them, polysaccharide PS-A has particularly excellent phylactic effects.
(II) Test for judging immunostimulating effects
(1) Macrophage phagocytic function test
.circle.1 Reticuloendothelial function test:
A sample was administered into the intraperitoneal injection of 7-weeks-old male mice of the ICR/JCL strain having a body weight of about 30 g (each group consisting of 5 mice) once a day continuously for five days (5 times in total). Phosphate buffered physiological saline solution (hereinafter referred to as "PBS") was given to a control group.
In order to examine influences on the phagocytosis in the reticuloendothelial system, colloidal carbon (Pelikan Drawing Ink 17 Black produced by Gunther Wagner Co., Ltd., West Germany) was injected into tail veins of the respective mice of the treated group and control group after passage of 24 hours from the last treatment, and the clearance from blood was examined according to the following procedures. More specifically, colloidal carbon was diluted with a physiological saline solution containing 3% of gelatin so that the carbon concentration was reduced to 1/2 and the dilution was injected into the tail vein at a rate of 10 ml/kg body weight. Then, 0.010 ml of blood was collected by a heparin-treated microppipette according to the eyepit puncture method and immediately transferred into 2 ml of 0.1% Na.sub.2 CO.sub.3 to dissolve the blood. The absorbance at 650 nm was mesured by Hitachi Double Beam Model 124 (supplied by Hitachi Co., Ltd., Japan). The phagocytic index was determined by injecting the colloidal carbon dilution into the vein, collecting blood after passage of 2 minutes (t.sub.1) and 20 minutes (t.sub.2) and performing calculation based on the carbon concentrations (C.sub.1 and C.sub.2 : after passage of 2 minutes and 20 minutes, respectively) in samples bloods according to the following formulae: ##EQU1##
The obtained results are shown in Table 13.
TABLE 13______________________________________Results of reticuloendothelial function testItem Dose K.sub.2.sup.20 T 1/2 (min.)______________________________________polysaccharide PS-A- 0.47 mg 0.0192 .+-. 0.0055 16.70 .+-. 4.43treated groupControl group 0.0192 .+-. 0.0021 34.52 .+-. 9.82ReferencePolysaccharide PS-B- 0.72 mg 0.0151 .+-. 0.0049 21.33 .+-. 5.59treated groupControl group 0.0147 .+-. 0.0037 21.40 .+-. 4.29Polysaccharide PS-C 0.47 mg 0.0117 .+-. 0.0041 29.67 .+-. 13.30treated GroupControl group 0.0065 .+-. 0.0017 48.85 .+-. 11.52Extract A-treated 0.72 mg 0.0173 .+-. 0.0035 18.19 .+-. 4.43groupControl group 0.0087 .+-. 0.0029 40.05 .+-. 18.82Extract B-treated 0.72 mg 0.0178 .+-. 0.0032 16.88 .+-. 5.43groupControl group 0.0087 .+-. 0.0029 40.05 .+-. 18.82______________________________________ Note Each value of K.sub.2.sup.20 or T 1/2 indicates mean value .+-. standard delivation value.
The half-value period in blood was shortened to about 1/2 by administering polysaccharide PS-A or PS-C extract A or B. Thus, it has been confirmed that the reticuloendothelial system is activated.
.circle.2 Phagocytosis on Staphylococcus aureus:
A sample was administered subcutaneously to the back of each of 7- or 8-weeks-old female mice of the ICR/JCL stain having a body weight of about 27 g (each group consisting of 5 mice) once a day continuously for five days (5 times in total). PBS was given to a control group.
On the sixth day, the peritoneal cavity of each mouse of each group was washed with RPMI-1640 medium [G. E. Moore, The Journal of the American Medical Association, 199, pages 519-524 (1967)] (supplied by Nissui Seiyaku Co., Ltd., Japan) to collect peritoneal exudate cells, and the collected cells were pooled respectively. The peritoneal exudate cells were washed one time with RPMI-1640 medium under centrifugation (1,000 r.p.m., 5 min.), and then suspended in 10% FBS-RPMI-1640 medium (culture medium formed by adding 10% of inactivated Fetal Bovine Serum to RPMI-1640 medium). The cell suspension was adjusted to 1.times.10.sup.6 cells/ml by using Turk solution. Then 2 ml of the so obtained suspension was charged in a TD-15 bottle having 4 cover glass sheets attached thereto and culturing was conducted at 37.degree. C. for 60 minutes in a 5% CO.sub.2 incubator, and 0.1 ml of a suspension of Staphylococcus aureus 209P having a concentration of 4.times.10.sup.8 cells/ml was added and culturing was further conducted for 20 minutes to effect phagocytosis. After culturing, the culture liquid was washed 3 times with Hanks' solution [J. H. Hanks and R. E. Wallace, Proceedings of the Society for Experimental Biology and Medicine, 71 196 (1949) (supplied by Nissui Seiyaku Co., Ltd., Japan)]. The macrophage-adhering cover glass sheets were fixed by methanol and subjected to Giemsa staining to obtain samples for counting the number of phagocytized bacteria and 200 macrophages were counted in each cover glass sheet microscopical observation with oil immersion objective (1000 to 2000 magnifications) to determine the phagocytosis ratio. ##EQU2##
The obtained results are shown in Table 14.
TABLE 14______________________________________Results of macrophage phagocytosis test Activa- Phagocytosis tionItem ratio (%) index______________________________________Control group 20.5 .+-. 3.0 1.00Polysaccharide 0.2 mg/kg body wt./day 34.3 .+-. 3.6 1.67PS-A-treated 1.0 mg/kg body wt./day 33.5 .+-. 5.4 1.63group______________________________________ Note Each value of phagocytosis ratio indicates mean value .+-. standard deviation value.
The phagocytosis ratio is improved by administering polysaccharide PS-A.
Thus, it has been confirmed that macrophage phagocytic activity is enhanced by polysaccharide PS-A.
.circle.3 Chemotaxis tests:
A sample of polysaccharide PS-A was administered subcutaneously to 7-weeks-old female mice of the ICR/JCL stranin having a body weight of about 27 g (each group consisting of 5 mice) once a day continuously for five days. PBS was given to a control group.
On the sixth day, peritoneal exudate cells were taken out, suspended in 10% FBS.RPMI-1640 medium and adjusted to a concentration of 1.times.10.sup.6 cells/ml. The chemotaxis was examined by Boyden chamber method [Journal of Experimental Medicine; 115, 453 (1962)].
In the experiment, 0.2 ml of the RPMI-1640 medium containing 10% normal human serum was placed in a lower room and 0.2 ml of the thus prepared peritoneal exudate cell suspension was placed in an upper room and the incubation was effected by a 5% CO.sub.2 incubator at 37.degree. C. for 90 minutes.
A filter was taken out, fixed with methanol and subjected to Giemsa staining. The number of cells was counted by means of a microscope of 400 mangifications. The total number of the cells in five fields of view was counted and the average was determined. The results are shown in Table 15.
TABLE 15______________________________________Results of the chemotaxis tests Number of chemotactic ChemotaxisItem Dose cells index______________________________________Control group 0.2 (PBS)/mouse 556.3 .+-. 52.8 1.00Polysaccharide 0.04 mg/kg body 968.0 .+-. 42.0 1.74PS-A-treated wt./daygroup 0.2 mg/kg body 996.0 .+-. 81.1 1.79 wt./day 1.0 mg/kg body 1173.2 .+-. 71.5 2.11 wt./day______________________________________ Notes ##STR2## 2. The number of chemotactic cells indicates the mean value .+-. standard deviation value.
By the administration of polysaccharide PS-A, the number of chemotactic cells was increased.
Namely, polysaccharide PS-A exhibited an effect of enhancing the chemotaxis of macrophages. From the above macrophage function tests .circle.1 - .circle.3 , it is understood that polysaccharide PS-A remarkably enhances the macrophage function.
(2) Cellular immunity test
.circle.1 Cytotoxicity test
(A) BC-47 cell:
(a) A sample of polysaccharide PS-A was administered subcutaneously to the back of each of 8-weeks-old female mice of BALB/c strain haing a body weight of about 22 g (each group consisting of 5 mice) once a day continuously for three days (3 times in total). On the first day of application of polysaccharide PS-A, BC-47 cells (the strain derived from the bladder cancer rat of the ACI strain and cultured in generations in a test tube) were injected to the intraperitoneal injection at a rate of 1.times.10.sup.7 cells/mouse in both the polysaccharide PS-A-treated group and the control group to effect immunization. After 12 days from the immunization, the peritoneal cavity of each mouse of the above two groups and the normal mouse group was washed with RPMI-1640 medium to collect peritoneal exudate cells. The collected cells were pooled respectively, and the peritoneal cells were centrifugally washed 2 times with RPMI-1640 medium and 1 time with 20% FBS.RPMI-1640 medium and then suspended in the latter-mentioned medium. With respect to each group, the peritoneal exudate cell concentration was adjusted to 1.6.times.10.sup.5 cells/ml, 3.2.times.10.sup.5 cells/ml and 6.4.times.10.sup.5 cells/ml by cell number counting using trypan blue.
(b) BC-47 cells cultured in a test tube were suspended in 20% FBS.RPMI-1640 medium to form a viable cell suspension having a concentration of 8.times.10.sup.4 viable cells/ml.
(c) In a horizontal-bottom-type microplate for culturing of cells [Model N-1480 having 96 holes (wells); produced by NUNC Co., Ltd., Sweden], 0.1 ml/hole of the peritoneal exudate cell suspension (1.6.times.10.sup.4 cells) and 0.1 ml/hole of the test tube cultured BC-47 cell suspension (8.times.10.sup.3 cells) were subjected to culturing at 37.degree. C. for 24 hours in a 5% CO.sub.2 incubator, and then, 0.1 .mu.Ci of .sup.3 H-thymidine was added to each hole and culturing was conducted under the same conditions for 24 hours. The operation was carried out in the same manner as above using the peritoneal exudate cell suspension (3.2.times.10.sup.4 cells and 6.4.times.10.sup.4 cells, respectively).
(d) After completion of culturing, each hole was washed with PBS and BC-47 cells adhering and growing on the bottom face of the hole were treated by trypsin and collected on a filter paper by a cell harvester of minimush type (produced by Dynaetech Co., Ltd., England). The quantity of .sup.3 H uptake in the BC-47 cells in each hole (the number of .sup.3 H atoms destroyed per minute; dpm) was measured by a liquid scintillation counter (Model LSC-673; produced by Aloka Co., Ltd., Japan).
The propagation inhibition ratio was calculated according to the following formula:
(A-B)/A.times.100(%)
wherein A indicates the mean value quantity (M)(dpm/hole) of .sup.3 H uptake in BC-47 cells cultured singly and B denotes the mean value quantity (M) (dpm/hole) of .sup.3 H uptake in BC-47 cells cultured together with peritoneal exudate cells of the normal mouse, the immunized mouse or the immunized and polysaccharide PS-A-treated mouse.
The activation index was calculated according to the following formula:
C/D
wherein C designates the propagation inhibition ratio of the immunized and polysaccharide PS-A-treated mouse and D stands for the propagation inhibition ratio of the immunized mouse (polysaccharide PS-A was not treated).
The obtained results are shown in Table 16.
TABLE 16______________________________________Results of cytotoxicity test propaga- tion inhi- Activa- Quantity of bition ra- tionItem .sup.3 H uptake (dpm) tio (%) index______________________________________BC-47 cells 44529.7 .+-. 988.3 0 --cultured singlyNormal group T:E = 1:2 39623.0 .+-. 1944.2 11.0 -- T:E = 1:4 37826.2 .+-. 1661.2 15.1 T:E = 1:8 36726.0 .+-. 2212.0 17.5Control group T:E = 1:2 36788.6 .+-. 1968.7 17.4 1.00 T:E = 1:4 33248.1 .+-. 326.3 25.3 1.00 T:E = 1:8 24238.6 .+-. 950.4 45.6 1.00Polysaccharide T:E = 1:2 28629.4 .+-. 671.4 35.7 2.05PS-A-treated T:E = 1:4 25497.6 .+-. 913.8 42.7 1.69group T:E = 1.8 18302.8 .+-. 245.5 58.9 1.29______________________________________ Note In the column of "Quantity of .sup.3 H uptake (dpm)", T:E = (BC47 cell number):(peritoneal exudate cell number) and each value indicates mean value .+-. standard deviation value.
(B) P 815 Cells:
In the same manner as in (A), P 815 cells (the strain derived from masto-cytoma mouse of the DBA strain and cultured in generations in the abdomen of DBA mouse) were injected to the intraperitoneal injection at a rate of 5.times.10.sup.6 cells mouse. The spleen cells were taken out 7 days after the immunization and suspensions having concentrations of 2.5.times.10.sup.6 cells/ml and 5.0.times.10.sup.6 cells/ml were prepared. A suspension of P 815 viable cells was adjusted to a concentration of 2.0.times.10.sup.5 cells/ml. The quantity of .sup.3 H uptake was measured by means of a liquid scintillation counter. The quantity of .sup.3 H uptake, propagation inhibition ratio and activation index are shown in Table 17. In the test, polysaccharide PS-A was administered subcutaneously to the back of each mouse in a dose of 0.2 mg/kg body weight once a day continuously for 3 days (3 times in total).
TABLE 17______________________________________Results of cytotoxicity test Propa- gation inhi- Ac- bition tiva- Quantity of ratio tionItem .sup.3 H uptake (dpm) (%) index______________________________________P 815 cells 57674.7 .+-. 2075.6 0 --cultured singlyNormal group T:E = 1:12.5 50667.7 .+-. 1114.9 12.1 -- T:E = 1:25 41953.9 .+-. 27.3.8Control group T:E = 1:12.5 38320.5 .+-. 2930.1 33.6 1.00 T:E = 1:25 22609.6 .+-. 1324.9 60.8 1.00Polysaccharide T:E = 1:12.5 23429.6 .+-. 1706.3 59.4 1.77PS-A-treated T:E = 1:25 10309.1 .+-. 1709.5 82.1 1.35group______________________________________ Note In the column of "quantity of .sup.3 H uptake (dpm)" T:E = (P 815 cell number):(peritoneal exudate cell number) and each value indicates mean value .+-. standard deviation value.
Polysaccharide PS-A enhanced the effect of inhibiting the propagation of mouse effector cells such as (A) BC-47 cells and (B) P 815 cells.
.circle.2 Blast transformation tests:
(A) Immunostimulation test on normal mice:
(a) Polysaccharide PS-A was administered to the back of each of 8-weeks-old female mice of the ICR/JCL stain having a body weight of about 28 g (each group consisting of 5 mice) by subcutaneous injection once a day continuously for five days (5 times in total). On the sixth day, mesenteric lymph node was teased out in RPMI-1640 medium. After allowing to stand for a while, a supernate was taken and centrifuged at 1200 r.p.m. for 5 minutes. The precipitates were taken and suspended in 20% FBS. RPMI-1640 medium. The suspension was adjusted to a concentration of 2.times.10.sup.6 viable cells/ml according to a cell-number counting method using trypan blue. In control group, PBS was given to the back of each mouse by subcutaneous injection.
(b) In a horizontal-bottom-type microplate for culturing cells, 0.1 ml/hole of the cell suspension and 10 .mu.l/hole of sample were charged. After the culture at 37.degree. C. for 24 hours in a 5% CO.sub.2 incubator, 0.1 .mu.Ci of .sup.3 H-thymidine wad added to each hole and the culture was continued under the same conditions for 24 hours.
(c) After completion of the culture, each hole was washed with PBS and the cells adhering to the bottom face of the hole were collected on a filter paper by means of a cell harvester. The quantity of .sup.3 H uptake (dpm) in the cells in each hole was measured by a liquid scintillation counter. The results are shown in Table 18.
TABLE 18______________________________________Results of immunostimulation test on normal mice Ac- Quantity of tiva- .sup.3 H uptake tionSample Item (dpm) index______________________________________PHA* Control group 869.7 .+-. 61.4 1.00(20 mg/ (PBS-treated group)ml) Polysaccharide 0.04 4678.3 .+-. 872.2 5.38 PS-A-treated mg/kg body group wt./day 0.2 5758.9 .+-. 149.2 6.62 mg/kg body wt./day 1.0 5962.7 .+-. 438.8 6.86 mg/kg body wt./dayLPS** Control group 178.4 .+-. 55.6 1.00(50 mg/ (PBS-treated group)ml) Polysaccharide 0.04 447.1 .+-. 72.2 2.51 PS-A-treated mg/kg body wt./day 0.2 467.3 .+-. 43.4 2.62 mg/kg body wt./day 1.0 675.6 .+-. 71.5 3.79 mg/kg body wt./day______________________________________ Note 1. *PHA (phytohemagglutinin): A mitogen of Difco Laboratory Co. (U.S.A.) obtained from kidney beans. Effective on Tcells. 2. **LPS (Lipopolysaccharide) A mitogen of Difco Laboratory Co. (U.S.A.) obtained from gramnegative bacteria. Effective on Bcells. 3. Quantity of .sup.3 H uptake is shown by the mean value .+-. standard deviation value. ##STR3##
(B) Immunostimulation test on mice in the immunosuppressive state:
(a) 31.3 mg of cyclophosphamide was intraperitoneally injected each of 8-weeksold female mice of the ICR/JCL strain having a body weight of abou 28 g (each group consisting of 3 mice). On the same day, the subcutaneous injection of polysaccharide PSA into the back of the mouse was started. The injection was continued for 4 days (once a day). On the fifth day, mesenteric lymph node was teased out in RPMI1640 medium. After allowing t stand for a while, a supernate was taken and centrifuged at 1200 r.p.m. for 5 minutes. The precipitates were taken and suspended in 20% FBS.RPMI 1640 medium. The suspension was adjusted to a concentration of 2.times.10.sup.6 viable cells/ml according to a cellnumber counting metho using trypan blue. In control group, PBS was given to the back of each mouse by subcutaneous injection. Thereafter, the quantity of .sup.3 H uptake (dpm) was measured in the same manner as in items (b) and (c) in the immunostimulation test on normal mice (A). The results are shown in Table 19.
TABLE 19______________________________________Results of immunostimulation teston mice in the immunosuppressive state Ac- tiva- Quantity of.sup.3 H tionSample Item uptake (dpm) index______________________________________PHA Normal group* 8034.8 .+-. 612.5 --(20 Control group 2797.0 .+-. 475.1 1.00mg/ (PBS-treated group)ml) Polysaccharide 0.2 13404.7 .+-. 1852.1 4.79 PS-A-treated mg/kg body group wt./day 1.0 13573.7 .+-. 516.1 4.85 mg/kg body wt./day 5.0 14970.2 .+-. 383.6 5.35 mg/kg body wt.dayLPS Normal group* 913.6 .+-. 83.5 --(50 Control group 678.6 .+-. 75.6 1.00mg/ (PBS-treated group)ml) Polysaccharide 0.2 1584.5 .+-. 100.1 2.34 PS-A-treated mg/kg body group wt./day 1.0 2081.3 .+-. 313.1 3.07 mg/kg body wt./day 5.0 2922.1 .+-. 397.5 4.31 mg/kg body wt./day______________________________________ Note *Normal group: Group of mice to which PSB was injected (cyclophosphamide was not injected), i.e., group of mice in normal state.
It has been confirmed that by the administration of polysaccharide PS-A, the quantity of .sup.3 H uptake is increased in the normal mice (A) and restored to a value equal to or higher than that of the normal mice in the mice in the innumosuppressive state (B).
Namely, by the administration of polysaccharide PS-A, the cellular blast transformation by the mitogen is accelerated and the cellular immunity is enhanced.
From the above tests .circle.1 and .circle.2 , it has been confirmed that polysaccharide PS-A remarkably enhances the cellular immunity. It is apparent from the above macrophage function test (1) and cellular innunity test (2) that polysaccharide PS-A exhibited the immunosimulating effects.
(III) Acute toxicity test
The acute toxicity was tested according to Lichfield-Wilcoxon method [J. Pharm. Exp. Therm., 96, 99 (1949)] by using male mice of the ICR/JCL strain.
The results are shown in Table 20.
TABLE 20______________________________________Results of acute toxicity test Peroral IntravenousItem (mg/kg body wt./day) (mg/kg body wt./day)______________________________________Polysaccharide more than 3,000 more than 400PS-APolysaccharide more than 3,000 more than 600PS-BPolysaccharide more than 3,000 more than 400PS-CExtract A more than 3,000 more than 600Extract B more than 3,000 more than 600______________________________________
It has been confirmed that polysaccharides PS-A, PS-B and PS-C and extracts A and B have low toxicity.
From the results of tests (I)-(III), it has been confirmed that polysaccharide PS-A having the low toxicity and the phylactic effect can be used alone or in combination with antibiotics to form a phylactic agent.
Polysaccharide PS-A having the immunostimulating effect as well can be used for remedy of living animals.
Though the mechanisms of the effects of polysaccharide PS-A have not been fully elucidated, it has been concluded from the immunostimulating effect and phylactic effect that polysaccharide PS-A remarkably improves the vital defense mechanisms.
From this fact, the use of polysaccharide PS-A as a carcinostatic agent or an agent for preventing the metastasis of cancer and so on can be expected.
Polysaccharide PS-A may be administered to human body orally, by injection (intravenously, subcutaneously or intramuscularly) or in any other manner.
When polysaccharide PS-A is in the form of solid preparations for oral administration, the preparations may be tablets, granules, powders, capsules or the like. The preparations may contain additives, for example, an excipient such as a sacchride or cellulose preparation, a binder such as starch paste or methyl cellulose, a filler, a disintegrator and so on, all being ones usually used in the manufacture of medical preparations. In case polysaccharide PS-A is employed as oral liquid preparations, they may be of any form selected from aqueous preparations for internal use, suspensions, emulsions, syrups, etc., and further they may be in the form of dried products which are dissolved prior to the use.
When polysaccharide PS-A is orally administered to adults, they may be employed in a dose of 0.1.about.2 mg/kg per day. Here, of course, the dose may be increased or decreased appropriately depending on the conditions of disease, the age of the patient, the form of the preparation administered, etc.
Polysaccharide PS-A may be injected in the form of aqueous solutions, spensions or oily or aqueous emulsions, but usually the injections are prepared by dissolving or spending them in aqueous liquid media such as sterile water of physiologicl saline solutions. If necessary, conventionally used dissolving agents, stabilizers, preservatives, additives for preparing isotonic solutions, etc. may be added to the injections.
The thus obtained injection preparations are administered intravenously, intramuscularly, subcutaneously or in any other appropriate manner. When polysaccharide PS-A is administered to adults parenterally, they may contain 0.005 to 0.5 mg/kg per day. Of course, this dose level is increased or decreased appropriately depending on the conditions of disease, the age of the patient, the form of the preparation administered and the method of administration.
The machines and tools used in the present invention were as follows:
(i) Elementary analysis: Yanagimoto MT-2 Type (produced by Yanagimoto Co., Ltd., Japan)
(ii) Decomposition Point: Melting Point Determinator Identi-scope Type (produced by Mitamura Riken Co., Ltd., Japan)
(iii) pH: Toadenpa HM-5B Type (Toadenpa Co., Ltd., Japan)
(iv) Specific rotatory power: Perkin-Elmer 241 Type (produced by Perkin-Elmer Co., Ltd., U.S.A.)
(v) Infrared absorption spectrum: Hitachi 260-10 Type (produced by Hitachi Co., Ltd., Japan)
(vi) Ultraviolet absorption spectrum: Hitachi 124 Type Spectrophotometer (produced by Hitachi Co., Ltd., Japan)
(vii) Ultracentrifugation: Hitachi 55P-7 (RPS 56T Rotor) (produced by Hitachi Co., Ltd., Japan)
(viii) Electrophoresis: Joko PAV-200 (produced by Joko Co., Ltd., Japan)
(ix) Sephadex G: Polysaccharide dextran reacted with epichlorohydrin for three-dementional cross-linking into network (produced by Pharmacia Fine Chemical Co., Ltd., Sweden). Particles used for the present invention were as follows:
__________________________________________________________________________ Minimum treatment Minimum exclusion time for swelling Bed volume of Optimum area limit ofType (hour) swelled gel of molecular molecular weightof At At ml/g weight of of polysaccharidesgel 20-25.degree. 90-100.degree. dry gel polysaccharides (K.sub.d = 0)__________________________________________________________________________G-100 72 5 15-20 1,000-50,000 100,000G-150 72 5 20-30 1,000-100,000 150,000G-200 72 5 30-40 1,000-150,000 200,000__________________________________________________________________________ (x) Barrenworts used were obtained from Matsuura Yakugyo Co., Ltd., in Nagoya, Japan.

BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows the chromatogram for extract A; and
FIGS. 2 to 6 show the infrared absorption spectrums for polysaccharides PS-A, PS-B and PS-C and extracts A and B, respectively.

The present invention will now be described in detail with reference to the following preparation examples that by no means limit the scope of the present invention.
PREPARATION EXAMPLE 1
15 l of 50% ethanol (V/V) was added to 2 kg of finely devided, commercially available barrenwort (Epimedium koreanum, Nak. preduced in Korea) and the extraction was carried out under heating at 50.degree. C. on a water bath for 6 hours using a reflux condenser. After the extraction, the mixture was filtered while it was still warm and the residue was further extracted 3 times in the same manner as above, using 15 l of 50% ethanol (V/V) each time. All the filtrates were combined and then concentrated at 45.degree. C. under reduced pressure to obtain 10 l of an aqueous extract. The extract was charged in a separating funnel. 5 l of ethyl acetate was added thereto and the mixture was shaken sufficiently. Only the aqueous layer was recovered. The aqueous layer was further extracted 3 times in the same manner as above using 5 l of ethyl acetate each time. The aqueous layer was concentrated under reduced pressure and the residual ethyl acetate was distilled out. The residue was filtered. 30 l of ethanol was added to the filtrate and the mixture was stirred and left overnight. A precipitate thus formed was filtered. The precipitate was washed with 200 ml of ethanol and poured in 2 l of water. 8 l of ethanol was added thereto and the thus formed precipitate was filtered out. The precipitate was dried under reduced pressure to obtain 20 g of an extract. The extract was further subjected to the extraction with 1 l of water and filtered. The filtrate was concentrated to dryness under reduced pressure to obtain 16 g of an extract in the form of dark brown powder.
1 l of 0.02 Mol aqueous sodium sulfate solution was added to 16 g of the extract. The mixture was stirred under heating at 40.degree. C. and then filtered while it was still warm. 100 ml of 10% aqueous cetyltrimethylammonium bromide solution was added to the filtrate under heating at 30.degree.-40.degree. C. The mixture was kept at 37.degree. C. overnight and then centrifuged (3,000 r.p.m., 10 minutes) to obtain 1 l of a supernate. 3 l of ethanol was added to the supernate and the resulting precipitate (3.0 g) was filtered out. 1 l of water was added to 3.0 g of the precipitate and the mixture was stirred under heating at 40.degree. C. and then filtered while it was warm. The filtrate was further filtered through Millipore Filter AP 20 (142 mm diameter; produced by Nippon Millipore Limited, Japan) and Millipore Membrane Filter HA (142 mm diameter, 0.45 .mu.m pore diameter; produced by Nippon Millipore Limited, Japan). The filtrate was then subjected to the ultrafiltration through Millipore Pellicon Ultrafiltration Membrane PSAC (nominal molecular weight ultrafiltration value of 1,000; produced ty Nippon Millipore Limited, Japan) and the filtrate was removed. Then, 500 ml of water was added to the residue and the thus diluted residue was again subjected to the ultrafiltration. This operation was repeated three times. The filtration residue was taken and diluted with water to a volume of 250 ml. 1 l of ethanol was added thereto to obtain 2.0 g of extract A as a precipitate.
2.0 g of extract A was dissolved in 20 ml of water and treated with a Sephadex G-150 column (50 mm diameter .times.600 mm length; produced by Pharmcia Fine Chemical Co., Ltd., Sweden). By the elution with 10 ml of water each time, 150 fractions were obtained. A part (about 0.2 ml) of each fraction was color-developed with phenol-sulfuric acid method successively and absorbance at 490 nm (OD) was measured. Fractions corresponding to Fr-1 in FIG. 1 (elution fractions Nos. 30-51) were selectively collected, concentrated under reduced pressure and then freeze-dried to obtain 600 mg of polysaccharide PS-A. The product had the physicochemical properties shown above.
PREPARATION EXAMPLE 2
15 l of 50% ethanol (V/V) was added to 2 kg of finely devided, commercially available barrenwort (Epimedium koreanum, Nak. produced in Korea) and the extraction was carried out under heating at 50.degree. C. on a water bath for 6 hours using a reflux condenser. After the extraction, the mixture was filtered while it was still warm and the residue was further extracted 3 times in the same manner as above, using 15 l of 50% ethanol (V/V) each time. All the filtrates were combined and then concentrated at 45.degree. C. under reduced pressure to obtain 10 l of an aqueous extract. The extract was charged in a separating funnel. 5 l of ethyl acetate was added thereto and the mixture was shaken sufficiently. Only the aqueous layer was recovered. The aqueous layer was further extracted 3 times in the same manner as above using 5 l of ethyl acetate each time. The aqueous layer was concentrated under reduced pressure and the residual ethyl acetate was distilled out. The residue was diltered. 30 l of ethanol was added to the filtrate and the mixture was stirred and left overnight. A precipitate thus formed was filtered out. The precipitate was washed with 200 ml of ethanol and poured in 2 l of water. 8 l of ethanol was added thereto and the thus formed precipitate was filtered out. The precipitate was dried under reduced pressure to obtain 20 g of an extract. The extract was further subjected to the extraction with 1 l of water and filtered. The filtrate was concentrated to dryness under reduced pressure to obtain 16 g of an extract in the form of dark brown powder.
1 l of 0.02 Mol aqueous sodium sulfate solution was added to 16 g of the extract. The mixture was stirred under heating at 40.degree. C. and then filtered while it was still warm. 100 ml of 10% aqueous cetyltrimethylammonium bromide solution was added to the filtrate under heating at 30.degree.-40.degree. C. The mixture was kept at 37.degree. C. overnight and centrifuged (3,000 r.p.m., 10 minutes) to obtain 1 l of a supernate. 3 l of ethanol was added to the supernate and the resulting precipitate (3.0 g) was filtered out. 1 l of water was added to 3.0 g of the precipitate and the mixture was stirred under heating at 40.degree. C. and then filtered while it was warm. The filtrate was further filtered through Millipore Filter AP 20 (142 mm diameter; produced by Nippon Millipore Limited, Japan) and Millipore Membrane Filter HA (142 mm diameter, 0.45 .mu.m pore diameter; produced by Nippon Millipore Limited, Japan). The filtrate was then subjected to the ultrafiltration through Millipore Pellicon Ultrafiltration Membrane PSAC (nominal molecular weight ultrafiltration value of 1,000; produced by Nippon Millipore Limited, Japan) and the filtrate was removed. Then, 500 ml of water was added to the residue and the thus diluted residue was again subjected to the ultrafiltration. This operation was repeated three times. The filtration residue was taken and diluted with water to a volume of 250 ml. 1 l of ethanol was added thereto to obtain 2.0 g of extract A as a precipitate.
500 ml of water was added to extract A and the mixture was stirred under heating at about 40.degree. C. to obtain a solution. The solution was filtered while it was still warm. The thus obtained filtrate was subjected to the column chromatography (45 mm column diameter, 400 mm length) using Polyamide C-200 (produced by Wako Junyaku Co., Ltd., Japan). After the elution with 2 l of water, the fractions thus eluted out with water which exhibited positive reactivity in .alpha.-naphthol reaction were concentrated to dryness under reduced pressure to obtain 1.0 g of polysaccharide PS-B having the physicochemical properties shown above. Then, water used for the elution was replaced with 3 l of 1.4% aqueous ammonia solution to obtain fractions which exhibited positive reactivity in .alpha.-naphthol reaction. The fractions were concentrated to dryness under reduced pressure to obtain 0.8 g of extract B having the physicochemical properties shown above.
0.8 g of extract B was dissolved in 20 ml of water and subjected to the elution by means of a Sephadex G-150 column with 10 ml of water each time. A part (about 0.2 ml) of each fraction was color-developed with phenol-sulfuric acid method successively and absorbance at 490 nm (OD) was measured. The fractions which were color-developed in the initial stage with phenol-sulfuric acid were selectively collected, concentrated under reduced pressure and then freeze-dried to obtain 200 mg of polysaccharide PS-A. The product had the physicochemical properties shown above.
EXAMPLE 1
10 mg of the polysaccharide obtained in Preparation Example 2 was dissolved in 100 ml of physiological saline solution. 5 ml of the solution was charged in an ampoule and sealed. The ampoules thus prepared were sterilized by an ordinary method to obtain injections of the extract of the present invention.
EXAMPLE 2
0.5 mg of the polysaccharide obtained in Preparation Example 2 was charged in a vial. This product is to be dissolved in sterilized water at the time of use to obtain an injection.
EXAMPLE 3
1.0 g of the polysaccharide obtained in Preparation Example 1 was blended with 140 g of crystallized cellulose, 5 g of magnesium stearate and 4 g of talc in a twin-cylinder mixer for 5 minutes. The resulting powdery mixture was shaped into tablets by means of a pestle having a rounded edge, a flat face and a diameter of 8.0 mm by direct tableting method to obtain 1,000 tablets having a diameter of 8.0 mm, thickness of 3.0 mm and weight of 150 mg.
EXAMPLE 4
200 mg of the polysaccharide obtained in above Preparation Example 1 was blended with 99.8 g of lactose in a twin-cylinder mixer for 5 minutes. Portions (2 g) of the mixture were charged in aluminum tape packs the three sides of which had been sealed to obtain the powdery product.
EXAMPLE 5
1.0 g of the polysaccharide obtained in Preparation Example 1 was blended with 50 g of calcium hydrogen-phosphate, 2 g of aluminum sillicate, 95 g of crystalline cellulose and 2 g of magnesium stearate in a twin-cylinder mixer for 5 minutes. The mixture was further mixed well by passing the same through a sieve. By an ordinary method, 1,000 capsules each containing 150 mg of the mixture were obtained.
CAPABILITY OF EXPLOITATION IN INDUSTRY
As described above in detail, the polysaccharide PS-A is obtained from easily available plants belonging to the genus Epimedium. Thus, the polysaccharide PS-A can be produced relatively easily on a large scale by the extraction and isolation from the above-mentioned plants according to the process of the present invention. The polysaccharide PS-A exhibits remarkable phylactic and immunostimulating effects and, therefore, excellent clinical effects thereof are expected when it is used as a medicine. The phylactic agent or the immunostimulating agent containing the polysaccharide PS-A can be obtained easily by mixing the same with a pharmaceutically allowable diluent or carrier and it can be administered to human bodies easily.

Number	Date	Country
56-65892	Apr 1981	JPX
56-65893	Apr 1981	JPX
56-190202	Nov 1981	JPX
57-40438	Mar 1982	JPX

Number	Name	Date
4163780	Ishida et al.	Aug 1979
4229440	Murofushi et al.	Oct 1980
4409385	Nakajima et al.	Oct 1983

Polysaccharide PS-A obtained from barrenwort deriving from plants belonging to the genus Epimedium, process for preparation thereof and phylactic and immunostimulating agents comprising said polysaccharide PS-A effective component

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications

Abstract

Description

Claims

Priority Claims (4)

PCT Information

US Referenced Citations (3)